|
|
|
| Clinical Effect of Leizhu Monoclonal Antibody Injection combined with Compound Xueshuantong Capsule on age-related macular degeneration |
| YU Linbi, SONG Xiaoli, XING Yanfei |
| Shanghai Jiading Hospital of Traditional Chinese Medicine, Shanghai 201800, China |
|
|
|
|
Abstract Objective: To investigate the effects of Leizhuman injection combined with compound Xueshuantong Capsule on the changes of vascular endothelial growth factor, intraocular pressure and visual acuity in patients with age-related macular degeneration. Methods: 60 patients with age-related macular degeneration in our hospital were randomly divided into treatment group and control group, 30 cases in each group. The control group was given intravitreal injection of Leizhumab injection. The treatment groupwas given compound Xueshuantong capsule once a month on the basis of the control group. All patients were treated for 3 months. After treatment, the control group was given intravitreal injection of Leizhumab. Serum levels of vascular endothelial growth factor, CRP, CMT, CNV, intraocular pressure and visual acuity were measured. Results: After treatment, compared with the control group, the serum levels of vascular endothelial growth factor in the treatment groupwere significantly lower (P<0.05); the serum CRP levels in the treatment groupwere significantly lower (P<0.05); the levels of CMT, CNV in the treatment group were lower (P<0.05); The visual acuity (logMAR) and IOP level were significantly lower (P<0.05). Conclusion: The experimental results show that for age-related macular degeneration patients, Leizhumab injection combined with compound Xueshuantong capsule ophthalmic injection can reduce the levels of vascular endothelial growth factor and CRP in peripheral blood, and also reduce the contents of CMT and CNV, so as to lower the ocular blood pressure and improve the visual acuity. It has guiding significance for clinical practice.
|
|
|
|
|
|
[1] 杨立,陈芝清.年龄相关性黄斑变性的流行病学调查[J].中国老年学杂志,2012,32(20):4569~4570.
[2] 中华医学会眼科学分会眼底病学组.老年性黄斑变性临床诊断标准[J].眼科新进展,1986,6(4):14~15.
[3] 李娜,孙先勇.年龄相关性黄斑变性的发病机制及治疗研究现状[J].中国全科医学,2016,19(6):724~728,732.
[4] 韦金智.复方血栓通胶囊治疗眼底病的临床效果[J].中国处方药,2017,15(4):79~80.
[5] 林波.复方血栓通胶囊治疗眼底疾病的临床疗效观察[J].黑龙江医药,2016,29(2):254~256.
[6] 曾仁攀,梁小琼,王国平,等.新型抗VEGF融合蛋白Conbercept玻璃体腔注射治疗湿性年龄相关性黄斑变性的疗效评价[J].临床眼科杂志,2015,(3):216~219. |
|
|
|
2019, Vol. 25 
